SEC Form 4 · accession 0001477932-17-004613
Citius Pharmaceuticals, Inc. · CTXR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suren G Dutia
Director
Period of report
Sep 15, 2017
Accepted (ET)
Sep 19, 2017 · 9:42 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001506251
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Common StockF1 | $3.45 | Sep 15, 2017 | A | 10,000 | A | — | Sep 13, 2027 | Common Stock | 10,000 | 10,000 | D |
| Options to Purchase Common StockF2 | $8.10 | holding | — | — | — | — | Oct 8, 2025 | Common Stock | 26,667 | 26,667 | D |
Explanation of responses
- F1The options vest in full on the first anniversary of the vesting commencement date, September 13, 2018.
- F2The option granted vested and became exercisable as follows: the option to purchase 2,667 shares of common stock of the Company (the "Common Stock") vested on October 8, 2015, and the balance of the option to purchase shares of Common Stock vested in twelve (12) equal installments commencing on December 31, 2015. The option was issued pursuant to the Company's 2014 Stock Incentive Plan.
Remarks
All numbers reflect a 1-for-15 reverse stock split on June 9, 2017.